TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

TuHURA Biosciences (NASDAQ:HURA) received a new U.S. patent (No. 12,760,104) for its VISTA inhibitor, TBS-2025, covering bispecific/multi-specific antibodies and expanding treatment areas. The patent extends to 2042, protecting the company's VISTA franchise and potential collaborations, according to TuHURA.

Original reporting
Published Oct 13, 2026, 11:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 11:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 — source image
Decision brief

The 30-second read

$HURABullishLow
01

Why it matters

A granted, broadened US patent extends coverage for TBS-2025 and related antibody formats and combination uses, potentially strengthening the company’s IP moat and negotiating position.

02

Market read

For traders, this is a company-specific IP milestone that can modestly support sentiment, but it is not a clinical or regulatory catalyst.

03

What to watch

The release does not quantify commercial milestones, licensing likelihood, or how the new claims map to ongoing trial endpoints, which can limit immediate valuation impact.

Relevance 6/10Novelty 6/10Timing: today’s PR, no scheduled data event attached

Background

TuHURA is a Phase 3 immuno-oncology company developing TBS-2025, a VISTA-inhibiting antibody, and other immune-modulating candidates.

Company-level read

Ticker impact

$HURABullishMedium confidence
Context

TuHURA says USPTO issued Patent No. 12,760,104 covering its VISTA inhibitor TBS-2025, including bispecific/multispecific antibody claims and new indications.

Expected impact

Likely modest positive bias as investors price in improved defensibility, though the stock reaction may be muted without new clinical data.

Evidence & confidence

The release is a new, specific USPTO patent grant with extended term to 2042, but it does not provide trial results, regulatory decisions, or partnership terms.

Market effects

Reinforces ongoing investor focus on immune checkpoint pathway targets beyond PD-1, and the value of broad antibody IP in immuno-oncology.

No clear regional market linkage beyond US biotech sentiment.

Primarily US IP, but could influence global partnering discussions for VISTA-targeting antibodies.

Counterpoint

Patent breadth does not guarantee clinical differentiation; investors may discount IP value if efficacy and safety data for TBS-2025 remain uncertain.

Key entities

  • TuHURA Biosciences, Inc.

    NASDAQ-listed immuno-oncology company developing VISTA inhibitor TBS-2025.

  • USPTO

    US Patent and Trademark Office that issued the new patent covering TBS-2025.

  • TBS-2025

    TuHURA’s VISTA inhibiting antibody referenced in the newly issued patent claims.

Related articles

$HURAMed

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., Nov. 13, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance

$HURAMed

TuHURA Biosciences Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences (NASDAQ: HURA) reported Q3 2026 results, highlighting progress in its immuno-oncology programs. The company shared early data from its IFx-2.0 study with Keytruda, showing durable responses in Merkel cell carcinoma patients. It also received FDA clearance for a Phase 1b study of its VISTA-inhibiting antibody, TBS-2025, in a subset of AML. TuHURA has $1.9M in cash and access to a $50M credit facility.

$HURAMedAI 8/10

TuHURA Reports Early Responses in Deep-Seated Merkel Cell Cancer Study

TuHURA Biosciences reported early responses in a study of its immunotherapy IFx-2.0 for deep-seated Merkel cell cancer. Preliminary results showed potential for use with checkpoint inhibitors, with five of eight patients in a prior study achieving durable responses. The company is conducting a Phase III trial comparing IFx-2.0 plus pembrolizumab to placebo, with enrollment expected to complete by Q3 or Q4 2024. TuHURA aims to discuss regulatory options with the FDA if data remains favorable.

$HURAHighAI 8/10

TuHURA reports tumor responses in 3-patient cancer trial

TuHURA Biosciences (HURA) reported partial tumor responses in 3 patients from a trial of IFx-2.0 combined with Keytruda for metastatic Merkel Cell Carcinoma. The Phase 1b/2a trial aims to enroll 9 patients and assesses safety and feasibility. The company is also conducting a Phase 3 trial. HURA hosted a webcast to discuss the initial data.

$HURALow

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

TuHURA Biosciences (NASDAQ:HURA) received a U.S. patent for its Delta Opioid Receptor (DOR) technology, covering uses in cancer treatments, including ADCs and cellular immunotherapies. The patent, valid until 2043, aims to enhance cancer immunotherapy effectiveness by targeting MDSCs. TuHURA is advancing preclinical models for blood-related cancers like AML and MDS.